Synaffix announced a $360M licensing agreement with Emergence Therapeutics, the 10th ADC developer to license their innovative ADC technology.
Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in upfront and milestone payments plus royalties on commercial sales. The first program will commence at signature, with the option to expand the collaboration to additional targets. The agreement is the result of positive proof of concept data following a successful initial discovery research collaboration between the companies.
Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.
Synaffix: “We are thrilled that Emergence has selected Synaffix as its long-term ADCtechnology partner and look forward to working closely together to build out their portfolio of ADC candidates.”
Read the full press release here.